Last reviewed · How we verify
Cephradin
Cephradin is a Small molecule drug developed by Sohag University. It is currently in Phase 2 development for Acute otitis media, Bacterial infection due to Klebsiella pneumoniae, Enterococcus Prostatitis. Also known as: Velosef.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cephradin |
|---|---|
| Also known as | Velosef |
| Sponsor | Sohag University |
| Target | Matrix metalloproteinase-9, Somatostatin receptor type 4, Bacterial penicillin-binding protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Approved indications
- Acute otitis media
- Bacterial infection due to Klebsiella pneumoniae
- Enterococcus Prostatitis
- Enterococcus Urinary Tract Infection
- Escherichia coli urinary tract infection
- Haemophilus Influenzae Acute Otitis Media
- Haemophilus influenzae pneumonia
- Infection due to Staphylococcus aureus
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disorder of joint
- Infective otitis media
- Klebsiella Prostatitis
- Klebsiella cystitis
- Lower respiratory tract infection
- Pharyngitis
- Pneumonia
- Pneumonia due to Streptococcus
- Prevention of Perioperative Infection
- Prostatitis
Common side effects
Key clinical trials
- Oral Versus Intravenous Antibiotic Prophylaxis Before Obstetric and Gynecological Procedures
- Efficacy of Oxybutynin in Paediatric Cystitis (PHASE4)
- Operational Research Management for Children With Severe Pneumonia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cephradin CI brief — competitive landscape report
- Cephradin updates RSS · CI watch RSS
- Sohag University portfolio CI
Frequently asked questions about Cephradin
What is Cephradin?
What is Cephradin used for?
Who makes Cephradin?
Is Cephradin also known as anything else?
What development phase is Cephradin in?
What does Cephradin target?
Related
- Target: All drugs targeting Matrix metalloproteinase-9, Somatostatin receptor type 4, Bacterial penicillin-binding protein
- Manufacturer: Sohag University — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Acute otitis media
- Indication: Drugs for Bacterial infection due to Klebsiella pneumoniae
- Indication: Drugs for Enterococcus Prostatitis
- Also known as: Velosef
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing